Background
Terumo Blood and Cell Technologies is aware of and is currently monitoring NAME:WRECK.
As a result, product technical teams are performing technical assessments to determine if NAME:WRECK presents a measurable cybersecurity risk.
Response
Terumo Blood and Cell Technologies is currently working with each product team and assessing if and how NAME:WRECK could be used to exploit our products. While some technical assessments have been completed, others are still ongoing.
Terumo Blood and Cell Technologies products that are confirmed to be unaffected by NAME:WRECK –
The product list below is available to customers to help identify existing Terumo Blood and Cell Technologies products that have been confirmed to be unaffected by NAME:WRECK. The list provided below is not comprehensive and may be updated as more products are assessed. It does not indicate the patch or device status.
- Reveos® Automated Blood Processing System
- FINIA® Fill and Finish System
- Cell Processing Application
- Trima Accel® Procedure Summary
- Vista® Information System
- Cadence® Data Collection System
- Spectra Optia® Apheresis System v11.x (v12.x still under review)
- Mirasol® Pathogen Reduction Technology
- InfoVu
- Trima KPI Dashboard
- TOMEs - Terumo Operational Medical Equipment Software
- Trucise® Data Management System
Customers that maintain patches independent of Terumo Blood and Cell Technologies delivery should ensure these actions are performed as the acting responsible entity in order to maintain the correct security posture of the system(s).
Terumo Blood and Cell Technologies products that are confirmed to be susceptible to the NAME:WRECK vulnerabilities –
The product list below is available to customers to help identify existing Terumo Blood and Cell Technologies products that have been confirmed to be susceptible to the NAME:WRECK vulnerabilities. The list provided below is not comprehensive and may be updated over time. It does not indicate the patch or device status.
- Trima Accel® Automated Blood Collection System
- Quantum® Cell Expansion System
Customers that maintain patches independent of Terumo Blood and Cell Technologies delivery should ensure these actions are performed as the acting responsible entity in order to maintain the correct security posture of the system(s).